Your email has been successfully added to our mailing list.

×
0.0553571428571429 0.125178571428571 0.196428571428571 0.160535714285714 0.231964285714286 0.125 0.119821428571428 0.0751785714285713
Stock impact report

Auris Medical Announces Acquisition of Orphan Drug Designation and Secures Rights to In-License Additional Patents Related to Betahistine

Auris Medical Holding AG (EARS) 
Last auris medical holding ag earnings: 8/10 06:31 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aurismedical.com
Company Research Source: GlobeNewswire
Acquires Orphan Drug Designation for betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS) Signs letter of intent to in-license two US patents covering use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD) Zug, Switzerland, December 6, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced a strategic expansion for its intranasal betahistine development program. In two related transactions, the Company has acquired an Orphan Drug Designation for betahistine in the treatment of obesity associated with Prader-Willi syndrome (PWS) and signed a binding letter of intent to in-license exclusive rights to two US Patents relating to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD), re Show less Read more
Impact Snapshot
Event Time:
EARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for EARS alerts
Opt-in for
EARS alerts

from News Quantified
Opt-in for
EARS alerts

from News Quantified